Difference between revisions of "Enoxaparin (Lovenox)"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [https://online.lexi.com/lco/action/login UpToDate Lexidrug], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information" to "please refer to your preferred pharmacopeias or the prescribing information") |
||
| (10 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Low molecular weight heparin, binds to antithrombin III, accelerating its activity and inhibiting factor Xa and thrombin.<ref name="insert">[http://products.sanofi.us/lovenox/lovenox.pdf Enoxaparin (Lovenox) package insert]</ref><ref>[[ | + | Class/mechanism: Low molecular weight heparin, binds to antithrombin III, accelerating its activity and inhibiting factor Xa and thrombin.<ref name="insert">[http://products.sanofi.us/lovenox/lovenox.pdf Enoxaparin (Lovenox) package insert]</ref><ref>[[:File:Enoxaparin.pdf | Enoxaparin (Lovenox) package insert (locally hosted backup)]]</ref><ref>[http://lovenox.com Lovenox manufacturer's website]</ref> |
<br>Route: SC | <br>Route: SC | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.<ref name="insert"></ref> |
==Patient drug information== | ==Patient drug information== | ||
| Line 11: | Line 11: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * | + | *1993-03-29: Initial FDA approval: prevention of DVT following hip replacement |
==Also known as== | ==Also known as== | ||
| − | + | *'''Brand names:''' Axoparin, Cardinex, Clexan, Clexane, Clotinex, Cnoxane, Cutenox, Dutenox, Enclex, Enox, Enxoaealth, Enoxol, Eparin, Lmwx, Lovenox, Markparin, Microparin, Noxprin, Pariparin, Xaparin | |
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
==References== | ==References== | ||
<references/> | <references/> | ||
| − | [[Category: | + | [[Category:Drugs]] |
| − | |||
[[Category:Subcutaneous medications]] | [[Category:Subcutaneous medications]] | ||
| Line 58: | Line 26: | ||
[[Category:Low molecular weight heparins]] | [[Category:Low molecular weight heparins]] | ||
| − | [[Category: | + | [[Category:Venous thromboembolism medications]] |
| + | |||
| + | [[Category:FDA approved in 1993]] | ||
Latest revision as of 01:00, 29 June 2024
General information
Class/mechanism: Low molecular weight heparin, binds to antithrombin III, accelerating its activity and inhibiting factor Xa and thrombin.[1][2][3]
Route: SC
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.[1]
Patient drug information
- Brief patient counseling information can be found on page 10 of the package insert[1]
- Enoxaparin (Lovenox) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 1993-03-29: Initial FDA approval: prevention of DVT following hip replacement
Also known as
- Brand names: Axoparin, Cardinex, Clexan, Clexane, Clotinex, Cnoxane, Cutenox, Dutenox, Enclex, Enox, Enxoaealth, Enoxol, Eparin, Lmwx, Lovenox, Markparin, Microparin, Noxprin, Pariparin, Xaparin